Besides, low-dose radiotherapy was also able to reverse tumor immune desertification and resistance to immunotherapy [32,33], and a proof-of-concept study revealed promising efficacy results in patients with metastatic NSCLC treated with triple combination therapy, consisting of low-dose radiotherapy, SRT and PD-1/PD-L1 inhibitors [34]. This evidence concerns the gene CD274 and neoplasm.